论文部分内容阅读
探讨拓扑替康 (topotecan ,TPT)联合依托泊苷 (etoposide ,Vp 16)、顺铂 (cisplatin ,DDP)组成的TEP方案治疗小细胞肺癌 (small celllungcancer ,SCLC)的临床疗效。 2 1例初治SCLC患者接受治疗 ,Vp 1670mg/ (m2 ·d) ,连用 5d ;TPT0 7mg/ (m2 ·d) ,于Vp 16后 1h应用 ,静脉滴入 3 0min ,连用 5d ;DDP 80mg/m2 ,分 3d静脉滴入。 2 1d为 1个周期 ,至少化疗 2个周期。 2 1例患者均可评价疗效。其中CR 8例 ,PR 8例 ,有效率 (RR)为 76 2 % ( 16/ 2 1) ,局限期 (LD)RR为90 0 % ( 9/ 10 ) ,广泛期 (ED)RR为 63 6% ( 7/ 11) ,其中 4例脑转移者PR 1例 ,SD 1例 ;全组患者中位生存期 11 5个月 ,1、2年生存率分别为 42 9% ( 9/ 2 1)和 19 0 % ( 4 / 2 1) ;2 1例患者均可评价不良反应 ,主要不良反应为骨髓抑制 ,Ⅲ～Ⅳ度白细胞减少的发生率 76 2 % ( 16/ 2 1) ,血小板减少的发生率为 61 9% ( 13 / 2 1) ,非血液学毒性主要为恶心、呕吐、脱发、乏力、肝肾功能异常等。TEP方案疗效肯定 ,能改善SCLC的生存期及生存率 ,可作为SCLC的一线治疗方案 ;主要不良反应为骨髓抑制 ,非血液学毒性轻微
To investigate the clinical efficacy of topotecan (TPT) combined with etoposide (Vp 16) and cisplatin (DDP) in the treatment of small cell lung cancer (SCLC). 21 patients with newly diagnosed SCLC were treated with Vp 1670mg / (m2 · d) for 5 days and TPT0 7mg / (m2 · d) for 1 hour after Vp 16. The patients were treated with intravenous infusion of 30 min for 5 days and DDP 80 mg / m2, sub-3d intravenous infusion. 2 1d for a period of at least 2 cycles of chemotherapy. 2 1 patients can evaluate the efficacy. Among them, 8 cases of CR and 8 cases of PR showed 76 2% (16/21) RR, 90 0% (9/10) RR and 63 6 ED (7/11). There were 4 patients with brain metastasis in 1 patient and 1 patient in SD. The median survival time was 11 5 months and the 1- and 2-year survival rates were 42.9% (9/21) And 19 0% (4/2 1), respectively. Adverse reactions were evaluated in 21 patients. The main adverse reactions were myelosuppression, the incidence of grade Ⅲ-Ⅳ leukopenia was 76.2% (16/2), and thrombocytopenia The incidence was 61.9% (13/21). The main non-hematological toxicities were nausea, vomiting, hair loss, fatigue, liver and kidney dysfunction. The positive curative effect of TEP regimen can improve the survival and survival rate of SCLC and can be used as the first-line treatment regimen for SCLC. The main adverse reactions are myelosuppression, mild non-hematologic toxicity